Offering infusion, specialty services

The past year has been eventful for Diplomat. In October 2014, the company went public with its first initial stock offering. But as it shifts its financial structure, Diplomat retains its core focus: Providing “medication management programs for people with complex chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, HIV, specialized infusion therapy and many other serious or long-term conditions” in all 50 states.

(Click here to view the full report.)



In March of this year, Diplomat acquired BioRx, a highly specialized pharmacy and infusion services company that provides treatments for patients with ultra-orphan and rare, chronic diseases. “The combined resources of both companies will make us much stronger and unique within the infusion services industry,” said chairman and CEO Phil Hagerman. The purchase, for $315 million in cash and Diplomat stock, gave a big boost to the company’s growing presence in drug infusion therapy.



Diplomat has been on a mission to vastly extend its reach into the infusion services market since December 2013, when it acquired AHF, which provides specialty drugs and infusion services for bleeding disorders. In June 2014, Diplomat also bought out MedPro, another specialty pharmacy focused on infusion for hemophilia and immune globulin.



Diplomat’s retail service division positions itself securely in that difficult terrain that lies between patients with serious chronic conditions who depend on complex, hands-on drug treatment regimens, and traditional pharmacy retailers that need outside expertise and help to serve those special-needs patients.



“Retail specialty services connects a retail pharmacy business to the specialty arena,” Diplomat stated. “Based on our broad industry experience, infrastructure and unique treatment-tracking software, retail specialty services.”